Hemab Therapeutics Holdings, Inc. COAG PHARMA
Company Overview
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Why Investors Should Care
Generates a return on equity of 36.2%, reflecting efficient use of shareholder capital.
Carries low leverage with a debt-to-equity ratio of 0.23.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +31.09% |
| 6 Months: | - |
| 3 Months: | +74.44% |
| 1 Month: | -10.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)43.58 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 36.2%.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | COAG Hemab Therapeutics Holdings, Inc. PHARMA | 44.57 | -25.04 | $2.08B | 0.00% | -38.09% | 36.18% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 16.56M | 23.61M |
| Operating Income | -16.56M | -23.61M |
| EBITDA | -16.48M | -23.54M |
| Interest Expense | - | - |
| Pretax Income | -15.50M | -22.68M |
| Tax Provision | -190.00K | 12.00K |
| Net Income | -15.31M | -22.69M |
| Diluted EPS | -16.18 | -0.51 |
| R&D Expense | 14.10M | 19.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 50.38M | 70.12M |
| Operating Income | -50.38M | -70.12M |
| EBITDA | -50.13M | -69.81M |
| Interest Expense | - | - |
| Pretax Income | -48.52M | -64.14M |
| Tax Provision | 185.00K | -227.00K |
| Net Income | -48.71M | -63.91M |
| Diluted EPS | -1.77 | -2.33 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 96.28M | 194.78M |
| Current Assets | 93.23M | 192.55M |
| Cash & Equivalents | 74.41M | 87.97M |
| Inventory | - | - |
| Receivables | 1.58M | 2.63M |
| Total Liabilities | 211.55M | 371.42M |
| Current Liabilities | 6.68M | 10.68M |
| Long Term Debt | - | - |
| Total Debt | 1.73M | 1.22M |
| Total Equity | -115.27M | -176.63M |
| Shares Outstanding | 44.19M | 44.19M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -45.59M | -61.48M |
| Investing Cash Flow | 61.90M | -81.48M |
| Financing Cash Flow | -100.00K | 156.30M |
| Capital Expenditure | -282.00K | -16.00K |
| Free Cash Flow | -45.87M | -61.49M |
| Net Change in Cash | 16.21M | 13.34M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 42.3% | 36.2% |
| ROCE % | -56.2% | -38.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 16.72% | 7.81M | $321.64M |
| 2 | Novo Holdings A/S | 8.95% | 4.18M | $172.20M |
| 3 | FMR, LLC | 7.92% | 3.70M | $152.31M |
| 4 | Capital International Investors | 7.72% | 3.60M | $148.44M |
| 5 | Deep Track Capital, Lp | 7.71% | 3.60M | $148.37M |
| 6 | Siren, L.L.C. | 4.47% | 2.09M | $85.96M |
| 7 | Avoro Capital Advisors LLC | 4.12% | 1.93M | $79.30M |
| 8 | Bain Capital Life Sciences Investors, LLC | 3.53% | 1.65M | $67.96M |
| 9 | JPMORGAN CHASE & CO | 2.47% | 1.15M | $47.47M |
| 10 | Vanguard Capital Management LLC | 1.67% | 780.76K | $32.16M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for COAG
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxNRzdjVkNJeTRxOFcwbC1BZHl6RWFZV3B4TUlyNVdvd2h1RUd0RTRRQUxmUzdpU1pJUlBqQUtEeFNULTNob2tRVWlYSDVRdXp6RkF4QWM3YjRRcFQyT2pCNGZJXzNNRGxGYTR6UV8wSXg1NkJfSnJsb3J0ZGdOMXF2WmI3OFFYd3R0ZWFReX…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE5KdjVOVWFBTG9HVTZVZXNKUGFEUmQ1WjdLbDRRaXlyTW5hcWpyVFdPMDhYMzg2OVJxSXhsem0zN1BhRG5xRFhtWEZIT2RualVX?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
COAG Stock Price and Chart — NASDAQ:COAG - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE11UFY0eFpaa2wwQ1pXY3B6a0l1Z0RDTjNNOVVEZURGc3JWTjRueF92aFJjTmZUV1diOFNiTVBISTlIWDdILUM2YUIxaEFxeTJvN1BTenB0Vl9GdUMt?oc=5" target="_blank">COAG Stock Price and Chart — NASDAQ:COAG</a…
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Historical Quotes - Nasdaq
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9sR3VwTnpkdmEzVHRzM05hQnZWY0pMOFRId3BsOXNFTjVDQTFQRUJnQ2pYMVhvOHFNZUFXZ3NRbTBOa19kVUIyZnRnRFl4c3RWeXZlM24xdDFCdlFpWVpYR0xZdXFyMGluazhEVUV3?oc=5" target="_blank">Hemab Therapeutics …
HEMAB THERAPEUTICS HOLDINGS (COAG) Stock Price, News & Analysis - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE9jUlJXcUoxaWcxVXQxQi0yeEEyZERTcGtJdW9Uajd5eC10a3k5cGhyLU9hZlk4THdISmlQNkVrS2lrN3M4Wk9wc0lfSDZuUjVIbzU4?oc=5" target="_blank">HEMAB THERAPEUTICS HOLDINGS (COAG) Stock Price, News & …
Citadel Advisors LLC Takes Position in Hemab Therapeutics Holdings, Inc. $COAG - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPU1ZldVk0MFhqa01hbXI2TEdZdGdKU29hWjNkdlFoS2dQRmlsN3RxZEhzcHd1UGxNS0JuSm9MMjlTaW5vcWhMWElSZjhoY3REcXlfay1TRDFWd3lEMXNMV1lwMVZHM1B1UnQ3SWE5aXg1c3VSOGFOWTI1cVdQMUctdmlqSURndmltQTNCeE…
COAG — Frequently Asked Questions
What is the current share price of Hemab Therapeutics Holdings, Inc. (COAG)?
As of 2026-09-19 21:16 PDT, Hemab Therapeutics Holdings, Inc. (COAG) trades at $44.57 on NasdaqGS. Its 52-week range is $24.98 to $54.94.
What is the market capitalisation of COAG?
Hemab Therapeutics Holdings, Inc. (COAG) has a market capitalisation of $2.08B on NasdaqGS.
What is the P/E ratio of COAG?
COAG trades at a trailing price-to-earnings (P/E) ratio of -25.04. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.58.
What is the return on equity (ROE) of COAG?
COAG has a return on equity (ROE) of 36.18%. Its return on capital employed (ROCE) is -38.09%.
Is COAG a good stock to buy?
This page provides a data-driven analysis of Hemab Therapeutics Holdings, Inc. (COAG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.